ECSP21029576A - Derivados de azitromicina y roxitromicina como fármacos senolíticos - Google Patents
Derivados de azitromicina y roxitromicina como fármacos senolíticosInfo
- Publication number
- ECSP21029576A ECSP21029576A ECSENADI202129576A ECDI202129576A ECSP21029576A EC SP21029576 A ECSP21029576 A EC SP21029576A EC SENADI202129576 A ECSENADI202129576 A EC SENADI202129576A EC DI202129576 A ECDI202129576 A EC DI202129576A EC SP21029576 A ECSP21029576 A EC SP21029576A
- Authority
- EC
- Ecuador
- Prior art keywords
- azithromycin
- senolytic
- activity
- telithromycin
- roxithromycin
- Prior art date
Links
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title abstract 5
- 230000009327 senolytic effect Effects 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 3
- 229960004099 azithromycin Drugs 0.000 abstract 4
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 abstract 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000002950 fibroblast Anatomy 0.000 abstract 2
- 229960005224 roxithromycin Drugs 0.000 abstract 2
- 229960003250 telithromycin Drugs 0.000 abstract 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 abstract 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 abstract 1
- 230000006536 aerobic glycolysis Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000004900 autophagic degradation Effects 0.000 abstract 1
- 230000002051 biphasic effect Effects 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 abstract 1
- -1 derivatives thereof Chemical compound 0.000 abstract 1
- 229960003276 erythromycin Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000006686 mitochondrial oxygen consumption Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 abstract 1
- 238000003210 sulforhodamine B staining Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta descripción expone el uso de azitromicina, roxitromicina y telitromicina, inclusive derivados de los mismos, como fármacos senolíticos. La BrdU se usó para inducir la senescencia en un modelo de líneas de células fibroblastos humanas. También se dan a conocer métodos para seleccionar compuestos por la actividad senolítica. El ensayo de SRB se usó para medir la viabilidad celular a través del contenido de proteínas. Se descubrió que la azitromicina, la roxitromicina y la telitromicina, productos farmacéuticos aprobados clínicamente, son fármacos senolíticos. Sin embargo, el compuesto precursor relacionado estrechamente, eritromicina, no mostró actividad senolítica. La azitromicina indujo considerablemente tanto glicólisis aeróbica como autofagia en fibroblastos humanos, pero mostró efectos bifásicos que incluían sobre las tasas de consumo de oxígeno mitocondrial con actividad inhibitoria a 50 µM y actividad estimuladora a 100 µM. El sistema de ensayo en tiempo real xCELLigenceMR mostró que la azitromicina focaliza preferentemente las células senescentes, eliminando aproximadamente 97% (casi una reducción de 25 veces en las células senescentes).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740137P | 2018-10-02 | 2018-10-02 | |
| US201862750559P | 2018-10-25 | 2018-10-25 | |
| US201962788187P | 2019-01-04 | 2019-01-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21029576A true ECSP21029576A (es) | 2021-05-31 |
Family
ID=70054763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202129576A ECSP21029576A (es) | 2018-10-02 | 2021-04-26 | Derivados de azitromicina y roxitromicina como fármacos senolíticos |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11957700B2 (es) |
| EP (1) | EP3860616B1 (es) |
| JP (1) | JP7538119B2 (es) |
| KR (1) | KR20210072026A (es) |
| CN (1) | CN113164504B (es) |
| AU (1) | AU2019353002B2 (es) |
| BR (1) | BR112021006423A2 (es) |
| CA (1) | CA3114888A1 (es) |
| CL (1) | CL2021000825A1 (es) |
| CO (1) | CO2021004427A2 (es) |
| CR (1) | CR20210221A (es) |
| CU (1) | CU24717B1 (es) |
| DO (1) | DOP2021000056A (es) |
| EC (1) | ECSP21029576A (es) |
| IL (1) | IL281879B2 (es) |
| MX (1) | MX2021003808A (es) |
| PE (1) | PE20211006A1 (es) |
| PH (1) | PH12021550719A1 (es) |
| SG (1) | SG11202103293UA (es) |
| WO (1) | WO2020072598A1 (es) |
| ZA (1) | ZA202102157B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200238A (es) * | 2017-11-24 | 2020-12-04 | Lunella Biotech Inc | Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas |
| CA3123850A1 (en) * | 2018-12-17 | 2020-06-25 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
| GB202014160D0 (en) * | 2020-09-09 | 2020-10-21 | Nuchido Ltd | Senolytic compounds and compositions |
| KR102673862B1 (ko) * | 2021-07-27 | 2024-06-10 | 전남대학교 산학협력단 | Sestrin2를 유전자가 삽입된 재조합 레트로바이러스 벡터를 포함하는 골 질환 예방 또는 치료용 약제학적 조성물 |
| US20250108036A1 (en) * | 2021-11-10 | 2025-04-03 | Lifeceutix Co., Ltd. | Compositions for removing senescent cells and uses thereof |
| WO2023090901A1 (ko) * | 2021-11-18 | 2023-05-25 | 의료법인 성광의료재단 | 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법 |
| IL328715A (en) * | 2023-11-30 | 2026-07-01 | Lunella Biotech Inc | Senolytic preparations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20022292A1 (it) * | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| EP2716647A3 (en) | 2004-02-27 | 2014-08-20 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
| PL2102226T3 (pl) * | 2006-12-12 | 2013-01-31 | Zambon Spa | Związki makrolidowe o aktywności przeciwzapalnej |
| GB0912584D0 (en) * | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
| US9180134B2 (en) * | 2011-08-18 | 2015-11-10 | Ecole Polytechnique Federale De Lausanne (Epel) | Mitochondrial ribosomal proteins as aging regulators |
| WO2013040206A1 (en) | 2011-09-14 | 2013-03-21 | Lewis Thomas J | Novel formulations comprising macrolide and tetracycline and their uses |
| KR101435717B1 (ko) * | 2012-09-06 | 2014-09-01 | 영남대학교 산학협력단 | 퀘세틴-3-Ｏ-β-Ｄ-글루쿠로니드를 유효성분으로 함유하는 세포 노화 억제용 조성물 |
| US20180021323A1 (en) * | 2015-01-22 | 2018-01-25 | Bioventures, Llc | Flip - a selective molecular target of senescent cells |
| JP7790686B2 (ja) | 2017-01-03 | 2025-12-23 | バイオアトラ インコーポレイテッド | 老化細胞の処置のためのタンパク質療法 |
| EP3596043B1 (en) | 2017-03-15 | 2025-12-03 | Lunella Biotech, Inc. | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast |
| US11427606B2 (en) * | 2017-04-20 | 2022-08-30 | Rising Tide Foundation | Azithromycin derivatives containing a phosphonium ion as anticancer agents |
| CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| JP6938682B2 (ja) | 2017-05-19 | 2021-09-22 | ルネラ・バイオテック・インコーポレーテッド | アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬 |
| US12006553B2 (en) | 2017-05-19 | 2024-06-11 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| CU20190106A7 (es) | 2017-06-26 | 2020-11-30 | Lunella Biotech Inc | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
| WO2019083997A1 (en) | 2017-10-24 | 2019-05-02 | Lunella Biotech, Inc. | MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES THAT REMOVE CANCER STEM CELLS (CSC) BY INHIBITING MITOCHONDRIAL BREATHING |
| CR20200238A (es) | 2017-11-24 | 2020-12-04 | Lunella Biotech Inc | Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas |
| CA3083487A1 (en) | 2017-12-01 | 2019-06-06 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US11559527B2 (en) | 2017-12-20 | 2023-01-24 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mDIVI-1 derivatives |
| CA3123850A1 (en) | 2018-12-17 | 2020-06-25 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
-
2019
- 2019-10-02 CU CU2021000024A patent/CU24717B1/es unknown
- 2019-10-02 IL IL281879A patent/IL281879B2/en unknown
- 2019-10-02 CR CR20210221A patent/CR20210221A/es unknown
- 2019-10-02 CA CA3114888A patent/CA3114888A1/en active Pending
- 2019-10-02 WO PCT/US2019/054231 patent/WO2020072598A1/en not_active Ceased
- 2019-10-02 EP EP19869744.3A patent/EP3860616B1/en active Active
- 2019-10-02 MX MX2021003808A patent/MX2021003808A/es unknown
- 2019-10-02 BR BR112021006423A patent/BR112021006423A2/pt unknown
- 2019-10-02 KR KR1020217012994A patent/KR20210072026A/ko not_active Ceased
- 2019-10-02 US US17/282,212 patent/US11957700B2/en active Active
- 2019-10-02 PE PE2021000425A patent/PE20211006A1/es unknown
- 2019-10-02 AU AU2019353002A patent/AU2019353002B2/en active Active
- 2019-10-02 JP JP2021518508A patent/JP7538119B2/ja active Active
- 2019-10-02 SG SG11202103293UA patent/SG11202103293UA/en unknown
- 2019-10-02 CN CN201980079188.4A patent/CN113164504B/zh active Active
-
2021
- 2021-03-30 ZA ZA2021/02157A patent/ZA202102157B/en unknown
- 2021-03-31 DO DO2021000056A patent/DOP2021000056A/es unknown
- 2021-03-31 CL CL2021000825A patent/CL2021000825A1/es unknown
- 2021-03-31 PH PH12021550719A patent/PH12021550719A1/en unknown
- 2021-04-09 CO CONC2021/0004427A patent/CO2021004427A2/es unknown
- 2021-04-26 EC ECSENADI202129576A patent/ECSP21029576A/es unknown
-
2024
- 2024-02-15 US US18/442,204 patent/US12208111B2/en active Active
- 2024-12-19 US US18/987,745 patent/US20250120994A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202102157B (en) | 2022-09-28 |
| US20240180944A1 (en) | 2024-06-06 |
| CO2021004427A2 (es) | 2021-04-30 |
| KR20210072026A (ko) | 2021-06-16 |
| US20210275560A1 (en) | 2021-09-09 |
| CR20210221A (es) | 2021-06-24 |
| EP3860616B1 (en) | 2024-08-21 |
| AU2019353002B2 (en) | 2024-11-14 |
| CU20210024A7 (es) | 2021-11-04 |
| IL281879B2 (en) | 2026-04-01 |
| EP3860616A1 (en) | 2021-08-11 |
| CL2021000825A1 (es) | 2021-10-22 |
| CA3114888A1 (en) | 2020-04-09 |
| IL281879B1 (en) | 2025-12-01 |
| WO2020072598A1 (en) | 2020-04-09 |
| US11957700B2 (en) | 2024-04-16 |
| MX2021003808A (es) | 2021-05-27 |
| PE20211006A1 (es) | 2021-06-01 |
| DOP2021000056A (es) | 2021-06-30 |
| EP3860616A4 (en) | 2022-07-06 |
| CN113164504A (zh) | 2021-07-23 |
| IL281879A (en) | 2021-05-31 |
| BR112021006423A2 (pt) | 2021-07-06 |
| PH12021550719A1 (en) | 2021-12-06 |
| US12208111B2 (en) | 2025-01-28 |
| AU2019353002A1 (en) | 2021-05-06 |
| US20250120994A1 (en) | 2025-04-17 |
| SG11202103293UA (en) | 2021-04-29 |
| JP2022504204A (ja) | 2022-01-13 |
| JP7538119B2 (ja) | 2024-08-21 |
| CN113164504B (zh) | 2024-12-13 |
| CU24717B1 (es) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021004427A2 (es) | Derivados de azitromicina y roxitromicina como fármacos senolíticos | |
| DOP2015000256A (es) | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas | |
| BR112014029115A8 (pt) | Composto, composição farmacêutica, e, uso de um composto ou composição | |
| BRPI0815708A8 (pt) | composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto | |
| PE20081055A1 (es) | Sistemas de espesamiento por surfactante que comprende celulosa microfibrosa y metodos para prepararlos | |
| CR10838A (es) | Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| BRPI0819319B8 (pt) | análogos de aminoglicosídeo antibacteriano | |
| ECSP066978A (es) | Compuestos amino y su uso como farmacéuticos | |
| BR112012012529A2 (pt) | composto indol e seu uso farmacêutico | |
| BR112016007408A2 (pt) | inibidores de metalo-beta-lactamase (mbl) compreendendo uma porção de quelação de zinco | |
| DE50313613D1 (de) | Mikro-/nanopartikel aus lipidhaltigen marinen organismen für pharmazie und kosmetik | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| CR20110519A (es) | Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad glucocorticoide | |
| ECSP20023626A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| Kinoshita et al. | Bafilomycin A1 induces apoptosis in PC12 cells independently of intracellular pH | |
| WO2013182998A4 (en) | Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes | |
| EP3403656A4 (en) | COMPOSITION FOR PREVENTING, HEALING OR TREATING THE FEMALE CLIMATE SYNDROME WITH LOGANINE OR DERIVATIVES THEREOF AS AN ACTIVE SUBSTANCE | |
| AR072426A1 (es) | Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida | |
| GT200600106A (es) | Agentes endoparasiticidas | |
| AR099063A1 (es) | Uso de un agente químico para clarificación de fruta con carozo | |
| UY29925A1 (es) | Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento. | |
| BRPI0612164A2 (pt) | composição para aplicação tópica e uso de uma composição | |
| Iliyasu et al. | Effects of Experimental" Fasciola gigantica" Infection on Serum Testosterone Profiles in Relationship to Semen Characteristics of Yankasa Ram | |
| BR112022010524A2 (pt) | Uso de masitinibe para o tratamento da asma eosinófila |